Transdermal Patches and Oral Thin Films
LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) for the pharmaceutical industry.
NEWS
LTS and LIVZON enter into license and collaboration agreement
LTS Lohmann Therapie-Systeme AG and Livzon Pharmaceutical Group Inc. (000513.SZ,1513.HK), a leading PRC pharmaceutical company, announced today that the companies have entered into an exclusive license and collaboration agreement to develop and commercialize Asenapine TTS.
PATIENTS
Our patients’ well-being drives LTS
Using a patch to protect the wound and accelerate healing is well known – but patches can achieve much more than this. As transdermal therapeutic systems, they can replace tablets or injection solutions and release the active substance into the body via the skin, offering an innovative, straightforward and highly tolerable form of therapy.
PARTNERS
Your B2B partner for customized solutions
LTS is your B2B partner, without its own products in the pharmaceuticals market. LTS develops and manufactures transdermal therapeutic systems (TTS) and oral thin films (OTF) based on your specific active substance. Our solutions make it possible for you to broaden your product portfolio or to enable a substance to be used for therapy. From feasibility studies to pharmaceutical development and process development to production and packaging, LTS offers all the services you need from one partner.
TECHNOLOGY
LTS innovations for your success
There are currently 20 known substances that can be applied transdermally. LTS offers twelve of these substances as transdermal therapeutic systems, making many patients’ lives easier. In cooperation with its partners from the pharmaceutical industry, LTS has set milestones in terms of innovation. LTS’s many successful products are proof of this.
COMPANY
LTS – a strong, innovative company
LTS is the market leader in transdermal therapeutic systems (TTS) and oral thin films (OTF). Founded in 1984, LTS has become a strong and innovative specialist medium-sized company. As a global player, LTS is an attractive employer that is aware of its social responsibilities and is happy to commit to them.
INNOVATIONS
Innovative transdermal technologies from LTS
LTS’s research and development focuses on two new technologies to complement and expand the potential of alternative drug delivery systems. In addition to the permanent further development of LTS TTS and LTS OTF technologies, the company also develops innovative microneedle and the ‘active LTS TTS’ technology.
SOLUTIONS
LTS – your partner for innovative solutions
The development of new pharmaceutical drugs is a lengthy and complex process in which not every highly promising active substance eventually becomes a successful drug. This is often because developers only think to develop tablets, capsules or solutions – but LTS offers alternative, innovative approaches.